Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of PIRCHE scores and allograft injury in kidney transplant recipients.

Frontiers in immunology·2026
Same author

Clinical Spectrum and Outcomes in Hypertrophic Cardiomyopathy With Apical Aneurysms: A Large Multicenter International Cohort.

JACC. Advances·2026
Same author

Predictors of Long-Term Outcomes in Hypertrophic Cardiomyopathy: The NHLBI HCM Registry.

JAMA·2026
Same author

Cardiac MR Imaging of Flow Abnormalities in Hypertrophic Cardiomyopathy Phenotypes.

Magnetic resonance imaging clinics of North America·2026
Same author

The Physiology of Flow Cessation: A Call for Inclusion of Continuous-Wave Doppler Interrogation of the Midapical Left Ventricle in the Standard Hypertrophic Cardiomyopathy Protocol.

Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography·2026
Same author

Evolution and Transformation of Hypertrophic Cardiomyopathy From a High Risk to a Treatable Low Mortality Disease With Contemporary Clinical Research Strategies.

Journal of the American Heart Association·2026
Same journal

Socioeconomic inequalities in the association between diet quality and incident cardiovascular diseases: A prospective study in the Netherlands.

Progress in cardiovascular diseases·2026
Same journal

Beyond therapeutic maximalism: Prioritization and personalization in preventive therapies.

Progress in cardiovascular diseases·2026
Same journal

Multimodality imaging of vulnerable plaque: Are we there yet? A multifaceted perspective.

Progress in cardiovascular diseases·2026
Same journal

Beyond LDL-C: Triangulating residual risk via lipoprotein(a), remnant cholesterol, and vascular inflammation.

Progress in cardiovascular diseases·2026
Same journal

COVID-19 and coronary atherosclerosis: Unmasking and accelerating?

Progress in cardiovascular diseases·2026
Same journal

Mavacamten and left ventricular dysfunction in hypertrophic cardiomyopathy with left bundle branch block.

Progress in cardiovascular diseases·2026
See all related articles

Related Experiment Video

Updated: May 21, 2026

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

Can pharmacologic gradient reduction decrease mortality in hypertrophic cardiomyopathy?

Dan Musat1, Silviana Marineci, Mark V Sherrid

  • 1Valley Health System, (affiliate of Columbia University, College of Physicians and Surgeons), Ridgewood, NJ, USA.

Progress in Cardiovascular Diseases
|June 13, 2012
PubMed
Summary
This summary is machine-generated.

Pharmacologic therapy can reduce obstructive hypertrophic cardiomyopathy (HCM) gradients. This review explores if gradient reduction in milder HCM cases may decrease mortality, though randomized trials are lacking.

Related Experiment Videos

Last Updated: May 21, 2026

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Pharmacologic therapy is the primary approach for obstructive hypertrophic cardiomyopathy (HCM) symptom relief.
  • Surgical septal myectomy offers excellent prognosis but is reserved for severe, refractory cases.
  • No randomized trials exist to assess pharmacologic therapy's prognostic impact in HCM.

Purpose of the Study:

  • To review the potential benefits of pharmacologic gradient reduction in asymptomatic or mildly symptomatic obstructive hypertrophic cardiomyopathy (HCM) patients.
  • To evaluate if reducing the left ventricular outflow tract (LVOT) gradient pharmacologically may decrease HCM-related mortality.

Main Methods:

  • Review of existing literature on pharmacologic and surgical interventions for obstructive hypertrophic cardiomyopathy (HCM).
  • Analysis of studies evaluating gradient reduction therapies, including combined disopyramide and beta-blockade.
  • Examination of prognostic data related to gradient reduction in HCM.

Main Results:

  • Pharmacologic therapy is the first-line treatment for HCM symptoms.
  • Combined disopyramide and beta-blockade effectively reduces resting gradients, though less than surgery.
  • The prognostic impact of pharmacologic gradient reduction in milder HCM remains unevaluated by randomized trials.

Conclusions:

  • Surgical septal myectomy is associated with excellent prognosis for severe obstructive hypertrophic cardiomyopathy (HCM).
  • Pharmacologic management, particularly combined disopyramide and beta-blockade, can reduce gradients in HCM.
  • Further research, including randomized trials, is needed to determine if pharmacologic gradient reduction impacts mortality in patients with less severe obstructive hypertrophic cardiomyopathy (HCM).